The contract was designed to assess fifteen selected chemicals for their potential to cause adverse reproductive effects in the mouse by perinatal/postnatal evaluation. The experimental work was divided into two phases. The initial phase was to determine a minimum effective dose (MED) of the test chemical to be used subsequently in the reproductive phase.for the MED phase, each compound was administered by gavage, once daily, for eight consecutive days to separate groups of ten female cd-1 mice at five dose levels determined upon consultation with the sponsor. During each treatment period, the mice were observed twice daily for general health, mortality, and pharmacotoxic signs. Body weights were measured on days 1, 8, 12 and 16. The second phase of the study was the reproductive screen. The MED of each chemical, in the appropriate vehicle, was administered once daily by gavage to a group of 50 timed pregnant cd-1 mice during days 7 through 14 of gestation.